OUR NEWS AND EVENTS

Merck is active in dealmaking worldwide.

Come meet us at an upcoming event.

April 3-5, 2013   BioNetwork East
Miami, Florida, USA
April 22-25, 2013   BIO International Convention
Chicago, Illinois, USA
April 29-30, 2013   Allicense
San Francisco, California, USA
May 8-10, 2013   BIOtech 2013
Tokyo, Japan
May 14-16, 2013   BioTrinity
Newbury, Berkshire, United Kingdom
May 28-30, 2013   ChinaBio Partnering Forum
Beijing, China
May 29-June 3, 2013   BIOTECH China
Shanghai, China
May 31 - June 4, 2013   ASCO Annual Meeting
Chicago, Illinois, USA
June 4, 2013   BioVaria
Munich, Germany
June 10-12, 2013   IATI-Biomed Israel 2013
Tel Aviv, Israel
June 13, 2013   AngloNordic Biotech Conference
London, United Kingdom
June 21-25, 2013   ADA Annual Scientific Sessions
Chicago, Illinois, USA
April 1, 2013   Ra Pharmaceuticals Announces Broad Collaboration with Merck to Develop Cyclomimetics™
March 13, 2013   Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer's Disease
February 20, 2013   Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
February 12, 2013   Lycera Enters Into a Collaboration Agreement with Merck
January 8, 2013   Adimab Expands Collaborations with Merck and Lilly
January 2, 2013   Microbiotix Announces Exclusive Worldwide Licensing Agreement for HCV NS5B Non-Nucleoside Polymerase Inhibitors
December 18, 2012   Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program
November 12, 2012   ActoGeniX enters Research Collaboration with Merck
November 8, 2012   Merck and Regenstrief Institute Establish Evidence-based Care Collaboration
October 16, 2012   Theravance and Merck Sign Cardiovascular Disease Collaboration
October 15, 2012   AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
October 13, 2012   Merck Researchers Present BMD Data from a Phase II Study of Odanacatib, Merck's Investigational Cat-K Inhibitor for Post-Menopausal Osteoporosis
October 9, 2012   Vaxxas Initiates Research Collaboration with Merck
October 8, 2012   Delphi Genetics grants Merck License for the use of the StabyExpress™ system
October 2, 2012   Ablynx Collaborates with Merck to Develop Therapeutic Nanobody Candidates
August 24, 2012   Merck Signs Two Deals for Novel HIV Drug Candidates and Initiates Phase II Clinical Trial of MK-1439 for HIV
June 18, 2012   Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
May 22, 2012   Codexis Announces Three-Year Extension of Collaboration Agreement with Merck
May 2, 2012   Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules
April 16, 2012   Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)
April 10, 2012   Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation
March 26, 2012   Merck Lumira Biosciences Fund Launched
March 15, 2012   Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)
March 14, 2012   Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate’s In Silico Drug Design Technology
March 6, 2012   Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
March 5, 2012   Merck's Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial
February 22, 2012   Protein Sciences Licenses Proprietary expresSF+® Insect Cell Technology to Merck
February 15, 2012   Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil
January 9, 2012   Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck

At Merck, flexibility, innovation and creativity are at the heart of the way we work with partners around the world.

Our Licensing team works with partners to advance their science through drug discovery and development collaborations and licensing agreements that are mutually beneficial.

Our Commercial Partnerships team pursues business opportunities with partners to jointly deliver their products and ours to the marketplace.

Pamela Demain, MBA, CLP, Executive Director, Corporate Licensing
"We welcome partnerships at all stages of discovery and development. As our partner, you will find that Merck is highly committed to ensuring the success of the opportunity through high prioritization, close collaboration, and the excellence of our research, development, marketing, and sales organizations."
Pamela Demain, MBA, CLP
Executive Director, Corporate Licensing
TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.